Table 1.
Patient Background
| Characteristic | MTC (n = 8) | ATC (n = 10) | Total (N = 18) |
|---|---|---|---|
| Sex, female, n (%) | 5 (63) | 6 (60) | 11 (61) |
| Age, years, median (range) | 53 (18–72) | 72 (60–82) | 64 (18–82) |
| ≥60, n (%) | 1 (13) | 10 (100) | 11 (61) |
| ECOG PS, n (%) | |||
| 0 | 8 (100) | 9 (90) | 17 (94) |
| 1 | 0 | 1 (10) | 1 (6) |
| Extent of disease at study entry | |||
| Local | 0 | 1 (10) | 1 (6) |
| Regional | 0 | 0 | 0 |
| Distant | 8 (100) | 8 (80) | 16 (89) |
| Unknown | 0 | 1 (10) | 1 (6) |
| Most common anatomic location of target lesions at baseline | |||
| Lung, n (%) | 3 (38) | 3 (30) | 6 (33) |
| Mediastinal lymph node, n (%) | 4 (50) | 1 (10) | 5 (28) |
| Thyroid gland, n (%) | 1 (13) | 4 (40) | 5 (28) |
| Sum of target lesion size at baseline, mm, median (range) | 48.0 (26.0–103.0) | 75.5 (32.0–97.0) | 67.5 (26.0–103.0) |
| Target lesions at baseline, n, median (range) | 2.5 (1.0–4.0) | 1.5 (1.0–4.0) | 2.0 (1.0–4.0) |
| Time since initial diagnosis, weeks, median (range) | 88.9 (9.4–1044.1) | 22.4 (3.3–61.7) | 33.0 (3.3–1044.1) |
| Clinically evaluable unmeasurable lesions | |||
| Pulmonary miliary metastases, n (%) | 2 (25) | 2 (20) | 4 (22) |
| Prior anticancer therapy | |||
| Surgical therapy, n (%) | |||
| yes/no | 6 (75)/2 (25) | 7 (70)/3 (30) | 13 (72)/5 (28) |
| Systemic therapy, n (%) | |||
| yes/no | 1 (13)/7 (88) | 6 (60)/4 (40) | 7 (39)/11 (61) |
| Radiotherapy, n (%) | |||
| yes/no | 0/8 (100) | 7 (70)/3 (30) | 7 (39)/11 (61) |
ATC, anaplastic thyroid carcinoma; ECOG PS, Eastern Cooperative Oncology Group Performance Status; MTC, medullary thyroid carcinoma.